THE BOTTOM LINE
- High Financial Risk for Patent Deals: Settlement agreements that involve payments from a patent holder to a potential generic competitor now carry a confirmed, significant risk of multi-million euro fines from the European Commission.
- Lower Burden of Proof for Regulators: The EU court has solidified the view that “pay-for-delay” deals are a severe “restriction by object” infringement. This means regulators do not need to prove actual harm to the market to impose penalties, making these agreements incredibly difficult to defend.
- Urgent Strategy Review Required: CEOs and in-house counsel, particularly in the pharmaceutical sector, must urgently review their patent litigation and settlement strategies. Any transfer of value to a competitor must be justifiable by legitimate commercial reasons, completely separate from delaying their market entry.
THE DETAILS
The case centered on a patent settlement agreement between Cephalon, the originator of the sleep-disorder drug modafinil, and Teva, a generic drug manufacturer. As Cephalon’s key patents neared expiry, Teva was preparing to launch a competing generic version. Following patent litigation, the two companies reached a settlement where Teva agreed to delay the market entry of its generic drug. Crucially, this agreement included substantial payments and other commercial benefits flowing from Cephalon to Teva, a practice commonly known as a “reverse payment” or “pay-for-delay.” The European Commission investigated and, in 2020, fined both companies a combined €60.5 million, concluding the deal was an illegal pact to share markets and eliminate a competitor.
The General Court has now upheld the Commission’s decision in its entirety, dismissing the companies’ appeal. The Court’s reasoning is a critical lesson for business leaders. It confirmed that Teva was a “potential competitor,” and the payment it received from Cephalon was an “unexplained inducement” to abandon its competitive efforts. In essence, the Court viewed the deal not as a genuine resolution of a patent dispute, but as a transaction where the incumbent paid the challenger to stay out of the market. This, the Court affirmed, is one of the most serious types of anti-competitive behavior, amounting to a “restriction of competition by object.”
This judgment solidifies a stern warning for all patent-intensive industries. The Court has clarified that the mere existence of a patent does not give companies a free pass to pay off potential rivals to protect their market share. Any settlement involving a reverse payment will be subject to intense scrutiny. Businesses must now ensure that any financial transfers within patent settlements are demonstrably linked to legitimate costs or other commercial arrangements, and can be clearly distinguished from a payment aimed at preventing competition. Failure to do so exposes the company to severe regulatory action and crippling fines.
SOURCE
Source: General Court of the European Union
